Lexaria Bioscience - Warrants (11/01/2026) Return on Equity

The latest ROE for LEXXW is -163.18%. That is below the Healthcare sector average of 21.28%. Investors often review this figure alongside Lexaria Bioscience - Warrants (11/01/2026)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, LEXXW currently prints -163.18% for ROE, while the sector average sits near 21.28%. That is roughly 866.8% below the sector mean. Large gaps often invite a closer look at Lexaria Bioscience - Warrants (11/01/2026)'s growth, margins, and balance sheet.

Return on Equity shows how effectively Lexaria Bioscience - Warrants (11/01/2026) converts resources into returns. At -163.18%, LEXXW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LEXXW's ROE (-163.18%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Lexaria Bioscience - Warrants (11/01/2026)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.